Tirzepatide
Also known as: mounjaro, zepbound, tirz, GIP/GLP-1 dual agonist, lY3298176
Dual GIP/GLP-1 receptor agonist studied for weight loss and type 2 diabetes management.
Quick Reference
Tirzepatide - Research Images
PSO vial render · Scientific images from Wikipedia · Tap to enlarge
Overview
Anti-diabetic and anti-obesity medication
Tirzepatide is a gastric inhibitory polypeptide (GIP) analog and a GLP-1 receptor agonist. It is used as an antidiabetic medication to treat type 2 diabetes (T2D) and for weight loss. Tirzepatide is administered via subcutaneous injections. It is sold in several countries under the brand name Mounjaro for T2D treatment. In the United States, it is sold under the brand name Zepbound for weight loss and for the treatment of obstructive sleep apnea.
Mechanism of Action
Simultaneous GIP and GLP-1 receptor agonism amplifies insulin secretion, reduces glucagon, and induces satiety more powerfully than GLP-1 alone.
What is Tirzepatide?
Tirzepatide is a dual-action peptide drug that mimics two gut hormones at once: GLP-1 and GIP. Developed by Eli Lilly, it is approved as a prescription medicine for type 2 diabetes and weight management. In clinical trials it produced some of the largest weight reductions ever seen with a medication, which is why research interest in it exploded.
How It Works - Simply Explained
Tirzepatide is a single molecule designed to activate two hormone receptors at once: GLP-1 and GIP. Both are gut hormones involved in blood sugar control and appetite, and researchers found their effects stack. In study models, the dual action produced stronger appetite quieting and metabolic effects than hitting GLP-1 alone, which helps explain the record-setting trial results.
What Studies Have Found
Delivered about 21 percent average weight loss, a record for medication
In the 72-week SURMOUNT-1 trial, participants on the highest tirzepatide dose lost an average of 20.9 percent of body weight, with some losing far more. No approved medication had ever produced average losses that large in a major trial.
Jastreboff AM, et al., 2022, New England Journal of Medicine
Beat semaglutide head-to-head on blood sugar
The SURPASS-2 trial pitted tirzepatide directly against semaglutide 1 mg in type 2 diabetes. Tirzepatide lowered A1C more at every dose tested, confirming the dual-hormone design added real power beyond GLP-1 alone.
Frias JP, et al., 2021, New England Journal of Medicine
Dramatically improved sleep apnea in obesity
In SURMOUNT-OSA, tirzepatide cut the frequency of breathing interruptions during sleep by roughly half to two-thirds in adults with moderate-to-severe sleep apnea and obesity, a benefit researchers tied to the weight loss.
Malhotra A, et al., 2024, New England Journal of Medicine
Protected failing hearts in a landmark trial
The SUMMIT trial enrolled people with heart failure and obesity. Tirzepatide reduced the combined risk of heart-failure events and cardiovascular death, extending the drug's story from metabolism into cardiology.
Packer M, et al., 2024, New England Journal of Medicine
New finding added 2026-10-12: Lower COPD flare rates in a records study of diabetes patients
In a study published on 9 October 2026, researchers used health records to compare people who have both type 2 diabetes and COPD, a long-term lung condition, and who started tirzepatide with similar people who started other diabetes medicines. The tirzepatide group was linked to lower rates of COPD flare-ups, breathing complications, and death than two comparison groups. Because this was a look-back at records rather than a randomized trial, the authors say the pattern needs confirming in a proper trial.
Hsu WH et al., 2026, Frontiers in Pharmacology
Last updated 2026-10-12. New findings are added as published research appears.
Frequently Asked Questions
What is tirzepatide?
Tirzepatide is a dual GIP/GLP-1 receptor agonist developed by Eli Lilly, approved as a prescription medicine for type 2 diabetes and chronic weight management. Research-grade tirzepatide is also sold by chemical suppliers strictly for laboratory studies.
How is tirzepatide different from semaglutide?
Semaglutide activates only the GLP-1 receptor, while tirzepatide activates both GLP-1 and GIP receptors. In clinical trials, tirzepatide produced larger average weight loss and greater blood sugar reductions.
What does dual GIP/GLP-1 mean?
It means one molecule is engineered to switch on two different gut-hormone receptors. GIP and GLP-1 both influence insulin release and appetite, and activating both together produced stronger effects in trials than either pathway alone.
Is tirzepatide FDA approved?
Yes, as prescription medicines for type 2 diabetes and chronic weight management. Research-use tirzepatide from chemical suppliers is a separate laboratory product, not for human use.
What side effects were reported in trials?
Trial publications report a gastrointestinal profile similar to other drugs in this class: nausea, vomiting, and diarrhea, mostly early in treatment. Full safety tables are in the published SURMOUNT and SURPASS papers.
What is the difference between tirzepatide and retatrutide?
Tirzepatide is an approved dual agonist (GIP plus GLP-1). Retatrutide is an investigational triple agonist that adds glucagon receptor activation, and a head-to-head trial of retatrutide versus tirzepatide is expected to read out in December 2026.
What did the SURMOUNT trials find?
The SURMOUNT program tested tirzepatide for weight management and related conditions. SURMOUNT-1 found up to 20.9 percent mean weight loss, while later trials showed benefits for sleep apnea and heart failure in people with obesity.
Is tirzepatide a peptide?
Yes. It is a 39-amino-acid synthetic peptide, engineered from gut-hormone sequences for once-weekly action.
FDA News About This Compound
How to Compare Research Peptide Vendors: A Buyer's Checklist
How to compare research peptide vendors: a buyer's checklist covering lot-matched certificates of analysis, testing evidence, delivered pric...
Read article →
Third-Party Peptide Testing Explained: What Independent Labs Actually Check
Third-party peptide testing explained: what independent labs actually check, including identity by mass spectrometry, purity by HPLC, quanti...
Read article →
How to Read a Peptide Certificate of Analysis
Learn how to read a peptide certificate of analysis: identity testing with HPLC and mass spectrometry, purity percentages, batch and lot num...
Read article →
What Researchers Are Saying
Community Reports - Not Medical Advice
The following is aggregated from public forums, Reddit, and research communities. These are anecdotal reports from researchers only - not verified clinical data and not a recommendation of any kind.
Tirzepatide (also known as mounjaro, zepbound) is studied within the metabolic and weight management research community. Dual GIP/GLP-1 receptor agonist studied for weight loss and type 2 diabetes management.
Last updated October 28, 2026
Research status: active. Tirzepatide appears across metabolic and weight management research forums and academic literature. Researchers note this compound falls in the weight loss category.
Last updated October 28, 2026
What Do You Think of This Peptide?
Share your opinion or research experience with Tirzepatide. Comments are reviewed before appearing.